FIG 10.

EAV resistance to ALV requires an additional mutation in nsp2. (A and B) Huh7 cells in 96-well plates were infected with rEAV^wt (control) and the rEAV mutants rEAV-nsp2^H114R, rEAV^QYA, and rEAV^QYA-nsp2^H114R in the presence of 0 to 50 μM ALV (A) or CsA (B). Cells were incubated for 3 days and cell viability was monitored using a commercial assay. In addition, the cytotoxicity of ALV or CsA treatment only was monitored in parallel in mock-infected Huh7 cells (light gray line). Graphs show the results (average and SD) of a representative experiment that was performed in quadruplicate. All experiments were repeated at least twice.